Form 4: Quest Diagnostics SVP, Clinical Solutions, Karthik Kuppusamy, Reports Stock Sale

Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, reported the sale of 1,760 shares of common stock at $140 per share on April 29, 2024, according to a Form 4 filing.

Summary

• On April 29, 2024, Karthik Kuppusamy, SVP, Clinical Solutions at Quest Diagnostics, sold 1,760 shares of common stock at a price of $140 per share.
• Following the transaction, Kuppusamy directly owns 13,435 shares of Quest Diagnostics common stock.
• Kuppusamy also indirectly owns 358 shares through a trust and 1,551 shares through a 401(k) plan.
• The sale was executed under a pre-arranged Rule 10b5-1 sales plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Insider sales are common and do not necessarily indicate a negative outlook, especially when conducted under pre-arranged plans like Rule 10b5-1.
• Comparing Kuppusamy's transactions to those of other executives at Quest Diagnostics and similar companies (e.g., Labcorp, Mayo Clinic Laboratories) would provide a better understanding of the significance of this sale.
• The volume of shares sold is relatively small compared to the total outstanding shares of Quest Diagnostics.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the transaction is unlikely to significantly affect the company's operations, employees, customers, suppliers, or creditors.

Key Dates